Psychedelics like psilocybin, ketamine, LSD, and MDMA are currently the subject of discussion due to their alleged potential to treat mental health disorders.
By 2030, antidepressant drug sales worldwide are anticipated to exceed $20 billion. Currently, some investors are betting that psychedelic therapies will be able to capture a portion of that huge market.
Substances like psilocybin, ketamine, LSD, and MDMA are still illegal in many parts of the world due to their mind-bending properties.
That may assist in illuminating the reasons for the industry’s strong market doubts. Seven US-traded psychedelic stocks were examined and found to be close to their 52-week lows as of mid-February, with some falling more than 80% below their 52-week highs.
Meet Kuukua Eshun – The Filmmaker Focused On Mental Health And Other Women Issues
However, the drugs are supported by venture capital firms that invest in the new sector.
Psychedelic healthcare, according to some venture capitalists who make investments in psychedelic companies, is a very exciting field because it represents the pinnacle of drug development, clinics, and experimental treatments.
There is a possibility that cannabis could be legalized in a number of other nations as investor and medical community interest grows.
